{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T13:03:19Z","timestamp":1776949399995,"version":"3.51.4"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2022,11,19]],"date-time":"2022-11-19T00:00:00Z","timestamp":1668816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,11,19]],"date-time":"2022-11-19T00:00:00Z","timestamp":1668816000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Graefes Arch Clin Exp Ophthalmol"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1007\/s00417-022-05903-3","type":"journal-article","created":{"date-parts":[[2022,11,19]],"date-time":"2022-11-19T08:08:46Z","timestamp":1668845326000},"page":"1167-1175","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Addition of intravitreal carboplatin with melphalan for management of vitreous seeding in retinoblastoma"],"prefix":"10.1007","volume":"261","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2277-398X","authenticated-orcid":false,"given":"Hamid","family":"Riazi-Esfahani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Babak","family":"Masoomian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alireza","family":"Khodabandeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdulrahim","family":"Amini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Taghizadeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leila","family":"Boujabadi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shervin","family":"Sharifkashani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carol L.","family":"Shields","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9423-9650","authenticated-orcid":false,"given":"Fariba","family":"Ghassemi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,11,19]]},"reference":[{"key":"5903_CR1","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1001\/jamaophthalmol.2014.414","volume":"132","author":"F Ghassemi","year":"2014","unstructured":"Ghassemi F, Shields CL, Ghadimi H et al (2014) Combined intravitreal melphalan and topotecan for refractory or recurrent vitreous seeding from retinoblastoma. JAMA Ophthalmol 132:936\u2013941. https:\/\/doi.org\/10.1001\/jamaophthalmol.2014.414","journal-title":"JAMA Ophthalmol"},{"key":"5903_CR2","doi-asserted-by":"publisher","unstructured":"Shields CL, Bianciotto CG, Jabbour P et al (2011) Intra-arterial chemotherapy for retinoblastoma: report no. 1, control of retinal tumors, subretinal seeds, and vitreous seeds. Arch Ophthalmol 129(11):1399\u20131406.\u00a0https:\/\/doi.org\/10.1001\/archophthalmol.2011.150","DOI":"10.1001\/archophthalmol.2011.150"},{"key":"5903_CR3","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1001\/jamaophthalmol.2013.7666","volume":"132","author":"CL Shields","year":"2014","unstructured":"Shields CL, Manjandavida FP, Arepalli S et al (2014) Intravitreal melphalan for persistent or recurrent retinoblastoma vitreous seeds: preliminary results. JAMA Ophthalmol 132:319\u2013325. https:\/\/doi.org\/10.1001\/jamaophthalmol.2013.7666","journal-title":"JAMA Ophthalmol"},{"key":"5903_CR4","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1136\/bjophthalmol-2011-300498","volume":"96","author":"DH Abramson","year":"2012","unstructured":"Abramson DH, Marr BP, Dunkel IJ et al (2012) Intra-arterial chemotherapy for retinoblastoma in eyes with vitreous and\/or subretinal seeding: 2-year results. Br J Ophthalmol 96:499\u2013502. https:\/\/doi.org\/10.1136\/bjophthalmol-2011-300498","journal-title":"Br J Ophthalmol"},{"key":"5903_CR5","doi-asserted-by":"publisher","first-page":"740","DOI":"10.4103\/ijo.IJO_866_19","volume":"67","author":"FP Manjandavida","year":"2019","unstructured":"Manjandavida FP, Stathopoulos C, Zhang J et al (2019) Intra-arterial chemotherapy in retinoblastoma - a paradigm change. Indian J Ophthalmol 67:740\u2013754. https:\/\/doi.org\/10.4103\/ijo.IJO_866_19","journal-title":"Indian J Ophthalmol"},{"key":"5903_CR6","doi-asserted-by":"publisher","unstructured":"Ghassemi F, Shields CL (2012) Intravitreal melphalan for refractory or recurrent vitreous seeding from retinoblastoma. Arch Ophthalmol 130(10):1268\u20131271.\u00a0https:\/\/doi.org\/10.1001\/archophthalmol.2012.1983","DOI":"10.1001\/archophthalmol.2012.1983"},{"key":"5903_CR7","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1093\/jjco\/hyg113","volume":"33","author":"A Kaneko","year":"2003","unstructured":"Kaneko A, Suzuki S (2003) Eye-preservation treatment of retinoblastoma with vitreous seeding. Jpn J Clin Oncol 33:601\u2013607","journal-title":"Jpn J Clin Oncol"},{"key":"5903_CR8","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1136\/bjophthalmol-2011-301450","volume":"96","author":"FL Munier","year":"2012","unstructured":"Munier FL, Gaillard M-C, Balmer A et al (2012) Intravitreal chemotherapy for vitreous disease in retinoblastoma revisited: from prohibition to conditional indications. Br J Ophthalmol 96:1078\u20131083. https:\/\/doi.org\/10.1136\/bjophthalmol-2011-301450","journal-title":"Br J Ophthalmol"},{"key":"5903_CR9","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1097\/IAE.0000000000000253","volume":"34","author":"P Schaiquevich","year":"2014","unstructured":"Schaiquevich P, Carcaboso AM, Buitrago E et al (2014) Ocular pharmacology of topotecan and its activity in retinoblastoma. Retina 34:1719\u20131727. https:\/\/doi.org\/10.1097\/IAE.0000000000000253","journal-title":"Retina"},{"key":"5903_CR10","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1136\/bjophthalmol-2017-310641","volume":"102","author":"R Rao","year":"2018","unstructured":"Rao R, Honavar SG, Sharma V, Reddy VAP (2018) Intravitreal topotecan in the management of refractory and recurrent vitreous seeds in retinoblastoma. Br J Ophthalmol 102:490\u2013495. https:\/\/doi.org\/10.1136\/bjophthalmol-2017-310641","journal-title":"Br J Ophthalmol"},{"key":"5903_CR11","doi-asserted-by":"publisher","first-page":"445","DOI":"10.18240\/ijo.2018.03.15","volume":"11","author":"AMA Said","year":"2018","unstructured":"Said AMA, Aly MG, Rashed HO, Rady AM (2018) Safety and efficacy of posterior sub-Tenon\u2019s carboplatin injection versus intravitreal melphalan therapy in the management of retinoblastoma with secondary vitreous seeds. Int J Ophthalmol 11:445\u2013455. https:\/\/doi.org\/10.18240\/ijo.2018.03.15","journal-title":"Int J Ophthalmol"},{"key":"5903_CR12","unstructured":"Karkhaneh R, Pourmostadam B, Ghassemi F et al (2010) Toxic effect of intravitreal carboplatin detected by flattened electeroretinogram in a patient with retinoblastoma treated by chemoreduction and local treatments. Iran J Ophthalmol 22(3):57\u201360"},{"key":"5903_CR13","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1136\/bjophthalmol-2011-300829","volume":"96","author":"SJ Smith","year":"2012","unstructured":"Smith SJ, Pulido JS, Salom\u00e3o DR et al (2012) Combined intravitreal and subconjunctival carboplatin for retinoblastoma with vitreous seeds. Br J Ophthalmol 96:1073\u20131077. https:\/\/doi.org\/10.1136\/bjophthalmol-2011-300829","journal-title":"Br J Ophthalmol"},{"key":"5903_CR14","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1111\/ceo.13711","volume":"48","author":"S Lema\u00eetre","year":"2020","unstructured":"Lema\u00eetre S, Poyer F, Fr\u00e9neaux P et al (2020) Low retinal toxicity of intravitreal carboplatin associated with good retinal tumour control in transgenic murine retinoblastoma. Clin Experiment Ophthalmol 48:500\u2013511. https:\/\/doi.org\/10.1111\/ceo.13711","journal-title":"Clin Experiment Ophthalmol"},{"key":"5903_CR15","doi-asserted-by":"publisher","first-page":"e00814","DOI":"10.1002\/prp2.814","volume":"9","author":"A Khodabande","year":"2021","unstructured":"Khodabande A, Ghassemi F, Asadi Amoli F et al (2021) Ocular safety of repeated intravitreal injections of carboplatin and digoxin: a preclinical study on the healthy rabbits. Pharmacol Res Perspect 9:e00814. https:\/\/doi.org\/10.1002\/prp2.814","journal-title":"Pharmacol Res Perspect"},{"key":"5903_CR16","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1111\/aos.12990","volume":"94","author":"D S\u00fcsskind","year":"2016","unstructured":"S\u00fcsskind D, Hagemann U, Schrader M et al (2016) Toxic effects of melphalan, topotecan and carboplatin on retinal pigment epithelial cells. Acta Ophthalmol 94:471\u2013478. https:\/\/doi.org\/10.1111\/aos.12990","journal-title":"Acta Ophthalmol"},{"key":"5903_CR17","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1111\/j.1755-3768.1964.tb01723.x","volume":"42","author":"L Ericson","year":"1964","unstructured":"Ericson L, Karlberg B, Rosengren BH (1964) Trials of intravitreal injections of chemotherapeutic agents in rabbits. Acta Ophthalmol 42:721\u2013726. https:\/\/doi.org\/10.1111\/j.1755-3768.1964.tb01723.x","journal-title":"Acta Ophthalmol"},{"key":"5903_CR18","doi-asserted-by":"publisher","first-page":"141","DOI":"10.4103\/0301-4738.154390","volume":"63","author":"FP Manjandavida","year":"2015","unstructured":"Manjandavida FP, Shields CL (2015) The role of intravitreal chemotherapy for retinoblastoma. Indian J Ophthalmol 63:141\u2013145. https:\/\/doi.org\/10.4103\/0301-4738.154390","journal-title":"Indian J Ophthalmol"},{"key":"5903_CR19","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1097\/IAE.0000000000000903","volume":"36","author":"CL Shields","year":"2016","unstructured":"Shields CL, Douglass AM, Beggache M et al (2016) Intravitreous chemotherapy for active vitreous seeding from retinoblastoma: outcomes after 192 consecutive injections. The 2015 Howard Naquin Lecture. Retina 36:1184\u20131190. https:\/\/doi.org\/10.1097\/IAE.0000000000000903","journal-title":"Retina"},{"key":"5903_CR20","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s10147-003-0370-4","volume":"9","author":"M Inomata","year":"2004","unstructured":"Inomata M, Kaneko A (2004) In vitro chemosensitivity assays of retinoblastoma cells. Int J Clin Oncol 9:31\u201335. https:\/\/doi.org\/10.1007\/s10147-003-0370-4","journal-title":"Int J Clin Oncol"},{"key":"5903_CR21","first-page":"126","volume":"51","author":"X Hou","year":"2015","unstructured":"Hou X, Cheng Y, Zhang Q et al (2015) Efficacy of intravitreal carboplatin plus bevacizumab in refractory retinoblastoma. Zhonghua Yan Ke Za Zhi 51:126\u2013129","journal-title":"Zhonghua Yan Ke Za Zhi"},{"key":"5903_CR22","first-page":"1892","volume":"37","author":"JW Harbour","year":"1996","unstructured":"Harbour JW, Murray TG, Hamasaki D et al (1996) Local carboplatin therapy in transgenic murine retinoblastoma. Invest Ophthalmol Vis Sci 37:1892\u20131898","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"5903_CR23","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1076\/ceyr.16.7.663.5061","volume":"16","author":"S Friedrich","year":"1997","unstructured":"Friedrich S, Cheng YL, Saville B (1997) Drug distribution in the vitreous humor of the human eye: the effects of intravitreal injection position and volume. Curr Eye Res 16:663\u2013669. https:\/\/doi.org\/10.1076\/ceyr.16.7.663.5061","journal-title":"Curr Eye Res"},{"key":"5903_CR24","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1136\/bjophthalmol-2018-312037","volume":"103","author":"DH Abramson","year":"2019","unstructured":"Abramson DH, Ji X, Francis JH et al (2019) Intravitreal chemotherapy in retinoblastoma: expanded use beyond intravitreal seeds. Br J Ophthalmol 103:488\u2013493. https:\/\/doi.org\/10.1136\/bjophthalmol-2018-312037","journal-title":"Br J Ophthalmol"},{"key":"5903_CR25","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1016\/j.ophtha.2015.01.017","volume":"122","author":"JH Francis","year":"2015","unstructured":"Francis JH, Abramson DH, Gaillard M-C et al (2015) The classification of vitreous seeds in retinoblastoma and response to intravitreal melphalan. Ophthalmology 122:1173\u20131179. https:\/\/doi.org\/10.1016\/j.ophtha.2015.01.017","journal-title":"Ophthalmology"},{"key":"5903_CR26","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1007\/s10384-020-00743-2","volume":"64","author":"H Kiratli","year":"2020","unstructured":"Kiratli H, Ko\u00e7 I, \u00d6zt\u00fcrk E et al (2020) Comparison of intravitreal melphalan with and without topotecan in the management of vitreous disease in retinoblastoma. Jpn J Ophthalmol 64:351\u2013358. https:\/\/doi.org\/10.1007\/s10384-020-00743-2","journal-title":"Jpn J Ophthalmol"},{"key":"5903_CR27","doi-asserted-by":"publisher","first-page":"696787","DOI":"10.3389\/fphar.2021.696787","volume":"12","author":"YA Yousef","year":"2021","unstructured":"Yousef YA, Al Jboor M, Mohammad M et al (2021) Safety and efficacy of intravitreal chemotherapy (melphalan) to treat vitreous seeds in retinoblastoma. Front Pharmacol 12:696787. https:\/\/doi.org\/10.3389\/fphar.2021.696787","journal-title":"Front Pharmacol"}],"container-title":["Graefe's Archive for Clinical and Experimental Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-022-05903-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00417-022-05903-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-022-05903-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,28]],"date-time":"2023-03-28T07:10:08Z","timestamp":1679987408000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00417-022-05903-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,19]]},"references-count":27,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["5903"],"URL":"https:\/\/doi.org\/10.1007\/s00417-022-05903-3","relation":{},"ISSN":["0721-832X","1435-702X"],"issn-type":[{"value":"0721-832X","type":"print"},{"value":"1435-702X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,19]]},"assertion":[{"value":"9 June 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 October 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 November 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 November 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional review board of Tehran University of Medical Sciences and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards (IRB Code: IR.TUMS.FARABIH.REC.1397.030).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}